Our phototheranostic agent CD44-IR700 is expected to inhibit tumor growth and eliminate CD44-positive cell population by phototherapy in TNBC PDX models as long as CD44-overexpression is validated on the surface of patient-derived tumor cells. Here, CD44 is linked to neoplasm.